GT200900173A - Dispersión sólida de un antagonista de neuroquinina - Google Patents
Dispersión sólida de un antagonista de neuroquininaInfo
- Publication number
- GT200900173A GT200900173A GT200900173A GT200900173A GT200900173A GT 200900173 A GT200900173 A GT 200900173A GT 200900173 A GT200900173 A GT 200900173A GT 200900173 A GT200900173 A GT 200900173A GT 200900173 A GT200900173 A GT 200900173A
- Authority
- GT
- Guatemala
- Prior art keywords
- solid dispersion
- neuroquinine
- antagonist
- functional
- urinary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Abstract
SE DESCRIBE UNA DISPERSIÓN SÓLIDA QUE COMPRENDE N-[(R)- EPSILON-CAPROLACTAM-3-IL]-AMIDA DE ÁCIDO (4R) - 4 - [N´ - METIL - N´ - (3, 5 - BISTRIFLURUOROMETIL - BENZOIL )- AMINO]- 4 (3,4 - DICLOROBENCIL) - BUT - 2 ENOICO O UNA SAL FAMRMACEUTICAMENTE ACEPTABLE DEL MISMO Y UN VEHICULO. LAS COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHA DISPERSION SOLIDA SON ÚTILES PARA TRATAR PACIENTES QUIENES TIENEN TRASTORNOS DE MOTILIDAD FUNCIONAL DE LAS VISERAS, ESPECIALMENTE SINDROME DE INTESTINO IRRITABLE O DISPEPSIA FUNCIONAL, O TRASTORNOS URINARIOS DE LA VEJIGA, ESPECIALMENTE INCONTINENCIA URINARIA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06126964A EP1938804A1 (en) | 2006-12-22 | 2006-12-22 | Pharmaceutical formulation comprising neurokinin antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200900173A true GT200900173A (es) | 2010-06-24 |
Family
ID=37762542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200900173A GT200900173A (es) | 2006-12-22 | 2009-06-19 | Dispersión sólida de un antagonista de neuroquinina |
Country Status (25)
Country | Link |
---|---|
US (1) | US20100015225A1 (es) |
EP (2) | EP1938804A1 (es) |
JP (1) | JP2010513356A (es) |
KR (1) | KR20090092288A (es) |
CN (1) | CN101541309A (es) |
AR (1) | AR064622A1 (es) |
AU (1) | AU2007338359B2 (es) |
BR (1) | BRPI0720937A2 (es) |
CA (1) | CA2672402A1 (es) |
CL (1) | CL2007003767A1 (es) |
CO (1) | CO6180497A2 (es) |
EA (1) | EA200900827A1 (es) |
EC (1) | ECSP099450A (es) |
GT (1) | GT200900173A (es) |
IL (1) | IL198780A0 (es) |
MA (1) | MA31004B1 (es) |
MX (1) | MX2009006747A (es) |
MY (1) | MY145919A (es) |
NO (1) | NO20092722L (es) |
NZ (1) | NZ576987A (es) |
PE (1) | PE20081848A1 (es) |
TN (1) | TN2009000253A1 (es) |
TW (1) | TW200848056A (es) |
WO (1) | WO2008077591A2 (es) |
ZA (1) | ZA200903271B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201309635A (zh) * | 2006-02-10 | 2013-03-01 | Dow Agrosciences Llc | 殺蟲性之n-取代(6-鹵烷基吡啶-3-基)烷基磺醯亞胺(二) |
JPWO2010092925A1 (ja) * | 2009-02-12 | 2012-08-16 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
CN102395358A (zh) * | 2009-02-24 | 2012-03-28 | 诺瓦提斯公司 | Nk受体拮抗剂的用途 |
US8263119B2 (en) * | 2010-12-01 | 2012-09-11 | Shire Llc | Capsule formulations containing lanthanum compounds |
EP3698782B1 (en) | 2012-01-06 | 2024-05-15 | H. Lundbeck A/S | Carbamate compounds for use in therapy |
KR102055542B1 (ko) * | 2015-03-10 | 2019-12-13 | 시오노기 잉크 | 고체 분산체 |
KR20180004263A (ko) | 2015-05-11 | 2018-01-10 | 어바이드 테라퓨틱스, 인크. | 염증 또는 신경병성 통증의 치료 방법 |
SI3541807T1 (sl) | 2016-11-16 | 2022-01-31 | H. Lundbeck A/S | Kristalinična oblika zaviralca MAGL |
BR112019009992A2 (pt) | 2016-11-16 | 2019-08-27 | Abide Therapeutics Inc | formulações farmacêuticas |
JP2023523219A (ja) | 2020-04-21 | 2023-06-02 | ハー・ルンドベック・アクチエゼルスカベット | モノアシルグリセロールリパーゼ阻害剤の合成 |
CN111904960A (zh) * | 2020-05-19 | 2020-11-10 | 合肥合源药业有限公司 | 一种固体分散体及药用组合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3622677A (en) * | 1969-07-07 | 1971-11-23 | Staley Mfg Co A E | Compressed tablets containing compacted starch as binder-disintegrant ingredient |
JPH054919A (ja) * | 1990-07-25 | 1993-01-14 | Sankyo Co Ltd | チアゾリジン誘導体の固体分散体 |
MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
EP1028730B1 (en) * | 1997-11-03 | 2002-04-17 | Janssen Pharmaceutica N.V. | Compositions of lipid lowering agents |
WO1999049863A1 (fr) * | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Preparations a liberation prolongee |
AR028253A1 (es) * | 2000-03-16 | 2003-04-30 | Pfizer Prod Inc | Inhibidores de la glucogeno fosforilasa |
JP2004131393A (ja) * | 2002-10-08 | 2004-04-30 | Kowa Co | 易溶出性製剤 |
GB2394417A (en) * | 2002-10-24 | 2004-04-28 | Novartis Ag | Solid dispersion comprising a piperidine substance P antagonist and a carrier |
CN1874766A (zh) * | 2003-10-27 | 2006-12-06 | 诺瓦提斯公司 | 神经激肽拮抗剂在尿失禁治疗中的用途 |
GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
WO2006112649A1 (en) * | 2005-04-20 | 2006-10-26 | Ctc Bio, Inc. | Pharmaceutical composition containing sibutramine free base and manufacturing method thereof |
-
2006
- 2006-12-22 EP EP06126964A patent/EP1938804A1/en not_active Ceased
-
2007
- 2007-12-20 EP EP07857016A patent/EP2117511A2/en not_active Withdrawn
- 2007-12-20 CN CNA2007800435054A patent/CN101541309A/zh active Pending
- 2007-12-20 NZ NZ576987A patent/NZ576987A/en not_active IP Right Cessation
- 2007-12-20 EA EA200900827A patent/EA200900827A1/ru unknown
- 2007-12-20 US US12/520,312 patent/US20100015225A1/en not_active Abandoned
- 2007-12-20 AU AU2007338359A patent/AU2007338359B2/en not_active Ceased
- 2007-12-20 MX MX2009006747A patent/MX2009006747A/es not_active Application Discontinuation
- 2007-12-20 KR KR1020097012819A patent/KR20090092288A/ko not_active Application Discontinuation
- 2007-12-20 AR ARP070105788A patent/AR064622A1/es not_active Application Discontinuation
- 2007-12-20 CA CA002672402A patent/CA2672402A1/en not_active Abandoned
- 2007-12-20 JP JP2009541897A patent/JP2010513356A/ja active Pending
- 2007-12-20 BR BRPI0720937-1A patent/BRPI0720937A2/pt not_active IP Right Cessation
- 2007-12-20 MY MYPI20092111A patent/MY145919A/en unknown
- 2007-12-20 WO PCT/EP2007/011293 patent/WO2008077591A2/en active Application Filing
- 2007-12-21 TW TW096149580A patent/TW200848056A/zh unknown
- 2007-12-21 CL CL200703767A patent/CL2007003767A1/es unknown
-
2008
- 2008-01-02 PE PE2008000080A patent/PE20081848A1/es not_active Application Discontinuation
-
2009
- 2009-05-12 ZA ZA200903271A patent/ZA200903271B/xx unknown
- 2009-05-14 IL IL198780A patent/IL198780A0/en unknown
- 2009-06-17 CO CO09062883A patent/CO6180497A2/es not_active Application Discontinuation
- 2009-06-17 MA MA32008A patent/MA31004B1/fr unknown
- 2009-06-19 TN TNP2009000253A patent/TN2009000253A1/fr unknown
- 2009-06-19 GT GT200900173A patent/GT200900173A/es unknown
- 2009-06-22 EC EC2009009450A patent/ECSP099450A/es unknown
- 2009-07-17 NO NO20092722A patent/NO20092722L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2672402A1 (en) | 2008-07-03 |
PE20081848A1 (es) | 2009-01-19 |
JP2010513356A (ja) | 2010-04-30 |
KR20090092288A (ko) | 2009-08-31 |
CL2007003767A1 (es) | 2008-07-18 |
MY145919A (en) | 2012-05-15 |
WO2008077591A2 (en) | 2008-07-03 |
EP2117511A2 (en) | 2009-11-18 |
IL198780A0 (en) | 2010-02-17 |
AU2007338359A1 (en) | 2008-07-03 |
ECSP099450A (es) | 2009-07-31 |
MX2009006747A (es) | 2009-06-30 |
TW200848056A (en) | 2008-12-16 |
EP1938804A1 (en) | 2008-07-02 |
ZA200903271B (en) | 2010-04-28 |
AR064622A1 (es) | 2009-04-15 |
WO2008077591A3 (en) | 2009-04-09 |
CO6180497A2 (es) | 2010-07-19 |
CN101541309A (zh) | 2009-09-23 |
AU2007338359B2 (en) | 2011-04-28 |
BRPI0720937A2 (pt) | 2014-03-11 |
MA31004B1 (fr) | 2009-12-01 |
TN2009000253A1 (en) | 2010-10-18 |
NZ576987A (en) | 2011-10-28 |
NO20092722L (no) | 2009-07-21 |
US20100015225A1 (en) | 2010-01-21 |
EA200900827A1 (ru) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200900173A (es) | Dispersión sólida de un antagonista de neuroquinina | |
EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
EP2322219A3 (en) | Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease | |
WO2007022380A3 (en) | Bis-aryl amide compounds and methods of use | |
MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
EP1841426A4 (en) | TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
ATE475650T1 (de) | Positive allosterische chinolon-m1- rezeptormodulatoren | |
BRPI0607017B8 (pt) | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc | |
EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
MX2009004467A (es) | Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk). | |
EA200801481A1 (ru) | 5-(арилсульфонил)пиразолопиперидины | |
EA200970113A1 (ru) | Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н | |
WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
EA200802020A1 (ru) | Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1 | |
EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo | |
AR054260A1 (es) | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos | |
EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
BRPI0504758A (pt) | miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren |